MarginsXMarginsX
Home › Markets › Health Care › ALKS

Alkermes plc (ALKS)

ALKS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$46.53
-1.06% on the day
Market cap
$7.8B
Mid cap
Revenue · 2025
$1.5B
-5.2% on 2024
Net income · 2025
$241.7M
16.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1520262/000119312526068925/0001193125-26-068925-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALKS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIreland
IPO year1991
SEC CIK0001520262
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$1.5B
Net income$241.7M
Operating income$254.0M
Net margin16.4%
Operating margin17.2%
Revenue growth-5.2%
Cash$388.6M
Total assets$2.5B
P/E (computed)32.4×
P/S (computed)5.3×

Warning signs

Cash runway
Cash-flow positive
$631.3M cash at September 30, 2026
Share count, 1 year
+1.8%
2025-10-24 to 2026-10-30 · +0.7% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$10.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$631.3M cash; operating cash flow $60.7M a quarter.Report 2026-09-30
Shares outstanding168,043,540 (2026-10-30); 165,117,509 a year earlier; 166,881,286 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $10.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$480.1M$16.3M$93.5M$631.3M$1.5B$1.8B10-Q 2026-11-03
Q2 2026
2026-06-30
$496.0M$501K$145.2M$511.5M$1.5B$1.7B10-Q 2026-07-28
Q1 2026
2026-03-31
$392.9M-$66.5M-$165.7M$351.6M$1.5B$1.6B10-Q 2026-05-05
Q4 2025
2025-12-31
$384.5M$49.3M$170.1M$388.6M$0$1.5B10-K 2026-02-25
Q3 2025
2025-09-30
$394.2M$82.8M$101.7M$616.4MNo debt tags$1.5B10-Q 2026-11-03
Q2 2025
2025-06-30
$390.7M$87.1M$150.2M$521.2MNo debt tags$1.5B10-Q 2026-07-28
Q1 2025
2025-03-31
$306.5M$22.5M$98.8M$399.8MNo debt tags$1.5B10-Q 2026-05-05
Q4 2024
2024-12-31
$430.0M$146.5M$190.4M$291.1MNo debt tags$1.6B10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-05-13

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.5%
1 month+18.4%
3 months-4.9%
Year to date+68.1%
1 year+51.7%
From 52-week high-14.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
ABVXAbivax SA$83.61-4.53%$7.3B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier